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ABSTRACT (Word count: 232/250) 
Purpose: There is still controversy on brand name to generic (B-G) antiepileptic drugs 
(AEDs) substitution. 
Methods: To assess association between brand-to-generic (B-G) antiepileptic drug 
(AED) substitution and seizure-related hospitalization, we designed a case crossover 
using the French National Health Insurance Database. We identified a cohort of adult 
patients who filled a prescription in 2009-2011 for AEDs with at least one brand name 
and one generic form. The outcome date was defined as the date of hospitalization, 
coded G40.x or G41.x, with a G40/G41 hospitalization-free period of at least one 
year. Patients with a medical history of cancer and women who gave birth in 2009-
2011 were excluded. We required individuals to have regular dispensations of AEDs 
within the year preceding the outcome date. Free patients were defined as patients 
who had only brand-name dispensations before the control period. 
Results: 8,379 patients (mean age ± SD, 52.7 ± 18.8 years; sex ratio male/female, 
1.27) were analyzed. Discordant pairs were 491 with B-G substitution in the control 
period only and 478 with B-G substitution in the case period only; OR (95%CI) 0.97 
(0.86–1.10). No statistically significant interaction was detected among the four pre-
specified subgroup analyses (gender, age strata, free or non-free and strict AED 
monotherapy or not). Controlling for non-seizure-related hospitalizations made no 
material difference. Sensitivity analyses yielded similar results. 
Conclusions: B-G AED substitution was not associated with an elevated risk of 
seizure-related hospitalization. 
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INTRODUCTION 
Generic drugs have been developed to control healthcare costs.  
There are conflicting viewpoints regarding generic substitution, particularly towards 
antiepileptic drugs (AEDs). Potential difference in therapeutic response between 
bioequivalent products remains a concern, especially for older AEDs with a narrow 
therapeutic index (NTI) but also for newer, non-NTI AEDs 1-3. Clinicians worry about 
possible therapy failure, especially in controlled patients, as even a single 
breakthrough seizure may have severe consequences such as loss of driving license, 
of employment or injuries 4. 
Some US states and European countries recommend limiting the substitution of 
generic AEDs, the American Academy of Neurology opposing antiepileptic generic 
substitution without physician approval 1, 5-7. It is also not recommended to switch 
AEDs in seizure-free patients 4. 
Some studies argued for the association between generic substitution and a risk of 
breakthrough seizures: opinion studies among clinicians and patients 1, 8-11, 
observational cohort 12-15 or case-control studies 16-18. These studies present several 
methodological limits and most of them were sponsored by brand medication 
manufacturers. In contrast, studies argued for a lack of association between generic 
substitution and a risk of seizure: meta-analysis of clinical trials, but included few 
patients and were underpowered to detect true clinical differences 19, observational 
cohort 20, 21, case-control 22, 23 and case-crossover studies 24, 25. The study of Gagne 
et al 23 hypothesized that refilling a prescription for the same manufacturer’s AED 
might itself be associated with risk of seizure-related events, due to confounders. The 
odds ratio (OR) was 2.75 (95% CI 0.88-8.64) for refills that involved switching, 
yielding a refill-adjusted OR for switching of 1.19 (95% CI 0.35-3.99). 
All these studies did not provide a definite answer about the impact of brand-to-
generic substitution on controlled epilepsy patients, especially for valproic acid, 
carbamazepine and lamotrigine, which are not extensively studied in the case-control 
studies. The aim of the GENEPI study (‘GENeric substitution of antiEPIleptic drugs’) 
was to further assess the association between seizure-related hospitalization and 
generic substitution and provide the necessary evidence to inform clinician and 
patient decisions. 
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METHODS 
Data source 
We used data from the French national health insurance system (Système National 
d’Information Inter-Régimes de l’Assurance Maladie, SNIIR-AM with comprehensive 
data for all health spending reimbursements of affiliated subjects linked by a unique 
personal health number to the French hospital discharge database (Programme de 
Médicalisation des Systèmes d’Information; PMSI). The SNIIR-AM database contains 
basic demographic patient data such as age and gender of about 65 million 
individuals (99% of the French population). We used data covering the period 2009 
to 2011. 
Ethics 
The Institute on Health Data (Institut des Données de Santé) approved this study 
(No. 28, September 2011), as well as the French Data Protection Authority 
(Commission Nationale de l’Informatique et des Libertés [DE-2012-111]). 
Design 
We used a case-crossover design 26-28. We arbitrarily chose a 3-day induction period 
and a 3-month exposure window (i.e. “case period”) for primary analyses. The control 
period was then defined as the 3 months immediately preceding the case period in 
primary analyses.  
Study population 
We used data from all adult patients affiliated to the French national health insurance 
scheme, aged 18 years or more on January 2009, who had at least one 
reimbursement between 2009 and 2011 for at least one of the following AEDs: 
carbamazepine, lamotrigine, levetiracetam, topiramate, or valproic acid, referred to 
as selected AEDs. These drugs had a brand name and at least one “A-rated” generic 
form available on the French market by this time (2009-2011) and were widely 
prescribed for epilepsy, allowing identification of epilepsy patients. They were 
extracted from the SNIIR-AM databases using anatomical therapeutic chemical 
(ATC) classification codes (N03AF01, N03AX09, N03AX14, N03AX11 or N03AG01). 
Targeted AEDs, i.e. AEDs with at least one generic form available on the French 
market, were defined as the above selected AEDs plus oxcarbazepine (N03AF02) 
which is mostly used in combination. 
Patients with a medical history of cancer (all ICD-10 codes for cancer with LTD) and 
women who gave birth (hospitalization with ICD-10 codes O80-O84) within the study 
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period were excluded because of the high risk of repeated seizures as well as 
patients receiving fatty acid derivatives through formulations registered as mood-
stabilizing drugs such as valpromide (DEPAMIDE) or divalproex sodium 
(DEPAKOTE) who may be not epilepsy patients. 
Case ascertainment 
Cases were identified, using the PMSI database, as individuals with a seizure-related 
hospitalization between January 2010 and December 2011. We used ICD-10 codes 
G40.x (epilepsy) or G41.x (status epilepticus) as codes of interest in primary or 
secondary hospital discharge diagnosis position. The index event date was defined 
as the date of occurrence in the PMSI database of one of the abovementioned codes 
of interest with an hospitalization-free (for ICD-10 G40.x or G41.x) period of at least 
one year preceding the index event date (controlled epilepsy patients). We further 
required individuals to have regular dispensations of the same product for each 
targeted AED within the year preceding the index event date; this was defined as the 
dispensation of products having the same International Non-proprietary Name (INN) 
at the same strength per unit with the same number of units per box and the same 
dosage form. Regular dispensation (a proxy for medication adherence) was defined 
as at least ten dispensation claims within a year, keeping in mind that those 
dispensations are on a monthly basis in France. Thus, we excluded events that 
occurred in 2009 to ensure that exposure and hospitalization data were available for 
the 365 days prior to the index date for each case.  
Exposure and covariate assessment 
A generic substitution (switch from brand to generic) was defined as a dispensation 
of a generic drug that was preceded by a dispensation of a product having the same 
INN at the same strength per unit with the same number of units per pack and the 
same dosage form but corresponding to the brand-name counterpart. Of note, in 
France, drugs are delivered by pharmacist using individual pack with blisters; 
pharmacists are not filling individual patient containers like in the US. Branded and 
generic drugs are distinguishable in the SNIIR-AM database using the French drug 
identification numbers (CIP, Presentation Identifying Code), which are specific to 
each drug product marketed by each manufacturer; The CIP (7-digit code) identifies 
the various existing presentations (INN, market authorization holder, strength per 
unit, number of units per pack and dosage form). 
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Substitution was first considered as any substitution of at least one targeted AED. 
Due to the late availability on the French market of levetiracetam generic form 
(August, 2011), we excluded patients who switched before the index date from the 
levetiracetam brand to the generic. Substitution was then classified into two groups: 
narrow therapeutic index (carbamazepine and valproic acid) or not (lamotrigine, 
oxcarbazepine, topiramate). 
AED-free patients were defined as patients who had only targeted AED brand name 
dispensations before the control period; which means no prior exposure to AED 
generics before the control period. Conversely, patients who had at least one 
dispensation of the generic drug before control period were defined as AED non-free 
patients. 
Strict monotherapy was defined as dispensations of only one targeted AED and 
without any concurrent use of other AEDs during the year preceding the index event 
date. These other (non-targeted) AEDs were as follows: barbiturates, 
benzodiazepines (clonazepam, clobazam, diazepam), phenytoin, GABA analogs 
(gabapentin, pregabalin). No generic formulation of these drugs was available in the 
French market (e.g. phenytoin) or they were not specifically dedicated to epilepsy 
treatment (e.g. gabapentin). They were identified by their CIP number. 
We defined psychiatric disease based on selected ICD-10 codes justifying LTD 
inscription for psychiatric disorder (LTD 23). We also collected the occurrence of 
hospitalizations not related to seizure during both control and case periods. 
Statistical analysis 
Data were analyzed using standard methods for matched case-crossover data. Odds 
ratios (ORs) and 95% confidence intervals (95% CIs) for seizure-related 
hospitalizations were estimated using conditional logistic regression models.  
We introduced an interaction term between switch occurrence and user profile (AED-
free patient or not), strict monotherapy or not, age strata, or gender. Age strata were 
defined according to first and third quartiles. Statistical models were first built without 
any adjustment and then with adjustment for non-seizure-related hospitalizations 
during case and control periods. All analyses were conducted using the SAS 
statistical package (version 9.3; SAS Institute, Cary, N.C., USA). 
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Sensitivity analyses 
We reduced case and control periods to 28 days and we tested 1-day and 5-day 
induction periods. Analyses were also performed for B-G substitution of any targeted 
AEDs or narrow therapeutic index AEDs (carbamazepine and valproic acid). 
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RESULTS 
A total of 812,314 adults with at least one reimbursement between 2009 and 2011 for 
one of the selected AEDs, were identified in the SNIIRAM, of whom 132,927 were 
excluded because they had a diagnosis of cancer or had been pregnant or had 
received fatty acid derivatives through formulations registered as mood-stabilizing 
drugs (Figure 1). Of the remaining 679,387 patients [median age (quartiles) 51 years 
(38-66); sex ratio male/female, 0.85], 66,315 had been hospitalized for seizure; 
21,879 were excluded because of inadequate date(s) of hospitalization(s), too early 
(hospitalization in 2009) or too close, thus a one-year period free of seizure-related 
hospitalization was not observed. Of the remaining 44,436 patients, 8,407 had 
regular dispensation of targeted AEDs in the year preceding the index date. 
Subsequently, 28 patients with a substitution involving levetiracetam before the index 
date were excluded. 
Main analysis 
8,379 patients [median age (quartiles) 52 years (40-69); sex ratio male/female, 1.27] 
were included in the primary analysis (Tables 1 and 2). Table 1 depicts patients’ 
characteristics and AED patterns. The targeted AED claims were mainly valproic 
acid, followed by lamotrigine and carbamazepine. Two-thirds of our population 
received only one targeted AED, with 41% of patients on strict monotherapy. Mean 
numbers of accounting lines related to any healthcare provisions during the six month 
case-control period were quite similar between free and non-free patients: 38.8 ± 
45.5 vs. 39.4 ± 47.0. Of note healthcare provision encompassed all claims being 
reimbursed: not only physician visits, but also nurse visits, physiotherapy session, 
biological measurements and drug dispensation. 
The distributions of brand-to-generic antiepileptic drug (B-G AED) substitution in the 
six-month period preceding the index event dates are displayed in Tables 2 and 3. 
There were 969 discordant pairs: 491 with B-G substitution in the control period but 
not in the case period, and 478 with B-G substitution in the case period but not in the 
control period: odds ratio 0.97 (95% CI: 0.86–1.10). Results were consistent across 
the different AEDs (Table 3). A post-hoc power analysis showed that 969 discordant 
pairs provided 93% power at the 5% level of significance to detect an odds ratio of 
1.25. 
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Subgroup analyses and secondary analysis 
No statistically significant interaction was detected among the four pre-specified 
subgroup analyses (Table 4). The p value was equal to 0.11 for the interaction term 
between substitution and free/non-free status: OR (95%CI) 1.20 (0.90–1.61) for free 
patients and 0.93 (0.81-1.07) for non-free patients. Non-free patients had a mean ± 
SD number of B-G AED substitution within the 6 months prior to the control period of 
0.95 ± 1.36, which remains a rare event. In addition, substitution was evenly 
distributed in the 6-month, case-control period.  
Less than 25% of patients had a non-seizure related hospitalization in the 6-month, 
case-control period: 22.4% in free patients and 24.7% in non-free patients. When we 
considered a non-seizure-related hospitalization as an exposure, the OR (95%CI) 
was 1.30 (1.18–1.44), p < 0.0001. Controlling for this covariate made no material 
difference to the effect estimates for B-G AED substitution (Table 4). 
Sensitivity analyses 
Sensitivity analyses yielded results similar to primary analysis (Table 4 and Table 5).  
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DISCUSSION 
Based on the largest set of data to date, our findings support the absence of 
association between brand-to-generic antiepileptic drug substitution and the risk of 
seizure-related hospitalization for AEDs with or without a narrow therapeutic index in 
the target population for clinicians (i.e. seizure-free patients, controlled by a stable 
treatment). This result supports that the bioequivalence between generics and their 
branded counterparts means clinical equivalence and is consistent with the 
bioequivalence requirements established by the Food and Drug Administration 
(identical to those of the European Medicines Agency) which are intended to ensure 
that differences in bioavailability between generics and their brand-name 
counterparts are not greater than between-lot variations from a single manufacturer 
23, 29. 
By seeking an association in patients receiving stable therapy who had been seizure-
free for at least one year, this provides the best possible conditions to assess the 
impact of substitution on the clinical state of patients. Patients for whom loss of 
seizure control has the most serious medical and social consequences (e.g. injury, 
loss of driving license, loss of employment…) are stable patients. In our study, the 
eligibility of seizure-free patients is warranted by the absence of any G40/G41 ICD-10 
codes within the year preceding the index date and by continuous brand or generic 
use, resulting in only adherent patients being captured. Indeed, non adherence has 
been shown to be associated with increased seizure risk and a significantly higher 
incidence of hospitalization 20. Furthermore, the number of AEDs dispensed is a 
strong predictor of seizure-related events 24 and multiple AEDs are generally 
reserved for patients with more severe forms of epilepsy, thus making multiple AEDs 
a potential proxy for disease severity 22. Yet at least 40% of patients in our study 
sample were on strict AED monotherapy, mainly valproic acid. In a previous study 30, 
it was reported that AED monotherapy was the rule in stable epilepsy patients. The 
fact that the association remains non-significant in stable patients following strict 
monotherapy gives the result even more value. 
An individual’s risk for epilepsy exacerbations may increase with co-morbidities 22, 
which is confirmed when we considered a non-seizure-related hospitalization as an 
exposure. However, our results are unchanged when controlling for this covariate. 
In the study of Zachry et al 16, the percentage of patients experiencing a switch in the 
case group was highest in the three months prior to the index event (emergent 
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epilepsy-related care) whereas this percentage in the control group was highest only 
in the first month prior to the index event, with no discernible pattern thereafter. In our 
study, the switches were evenly distributed throughout the case and control periods 
and sensitivity analyses, by varying the duration of the case and control periods and 
the induction period, confirming the robustness of the results. 
It is of note that the analysis based on the 28-day case and control period gave 
consistent results but a less precise estimation.  
As regards confounding the advantage of the case-crossover method is that the 
influence of factors that vary among the participants, such as fixed between-person 
confounders, is removed. Previous studies 16-18 which found an association between 
A-rated formulations of AEDs and an increased risk of inpatient/emergency epilepsy 
care were limited by confounding on account of the severity of epilepsy. Using a short 
study period, confounding by time-varying factors is thought to be limited or unlikely. 
Imbalances were still possible in transient individual factors. Specifying the risk 
period requires particular caution as the estimator may be biased toward the null. 
Sensitivity analyses by modifying the end and duration of the risk period and control 
periods verified the robustness of our results. Generic AEDs have been available on 
the French market since 2000, thus no time-trend in exposure was anticipated 
excepted for levetiracetam. Using electronic health records allowed completeness 
and timeliness of information regarding drug dispensation and hospitalization dates. 
As regards selection bias, the completeness of the SNIIR-AM files narrowed 
concerns about external generalizability. 
We also have to consider ICD code accuracy and misclassification bias. However, 
these should be limited, given that most instances of seizures are readily evident for 
healthcare providers. Other users of AEDs for conditions such as bipolar disorder, 
neuropathic pain or migraine may also have been included in our study population 
(i.e. 24% of our patients have a previous psychiatric diagnosis). Nevertheless, AEDs 
indicated for diseases other than epilepsy were not selected, such as gabapentin. 
Moreover, studies have shown that the use of a combination of diagnosis codes and 
pharmacy claims of AEDs can correctly classify 90% of epilepsy cases 31 and the 
most accurate algorithm to identify epilepsy cases in administrative health data is 
IDC-10 codes G40/G41 32. 
The relevance of the choice of our outcome should be discussed: it is a highly 
specific outcome, which does not allow generalization of our results, because not all 
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patients with breakthrough seizures are hospitalized, some of them could be 
managed in an outpatient setting 16, 17, 24. These results are only applicable to serious 
exacerbations of epilepsy, as claims databases capture only the most serious events 
17, 21. However we assume, as other researchers, that stable patients experiencing 
unexpected breakthrough seizures are likely to seek care in emergency and inpatient 
settings more often than in ambulatory settings16-18.  
Switches are usually characterized as one of three types: brand to generic, generic to 
brand or generic to generic 16, 17, 24. As many healthcare providers focus on problems 
related to brand-to-generic switching, our survey has studied this type of switch, but 
the results could not be extended to switches among different generic formulations.  
Results were consistent across all targeted AEDs, either NTI AEDs or non-NTI AEDs, 
which is reassuring for the use of valproic acid or carbamazepine generic 
formulations. Nevertheless, no conclusion for phenytoin, another NTI AED, could be 
drawn because no generic formulation of phenytoin is marketed in France. 
 
Conclusion 
Previous studies suggested that switching AED medication may result in adverse 
events although the differences could be attributable to confounders which were not 
well accounted for. Our results allow exclusion of an association between a brand-to-
generic substitution and seizure-related hospitalization, in well-controlled, seizure-
free patients. These findings may restore confidence in AED generic formulations, 
keeping in mind that substitution should not be performed without physician and 
patient agreement. 
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Table 1 Patients’ characteristics and antiepileptic drug (AED) treatment patterns 
 
Variable 
All patients 
n = 8 379 
Free 
patients 
n = 4 088 
Non free 
patients 
n = 4 291 
Age at index date, median (Q1-Q3) 52 (40-69) 52 (38-70) 52 (40-67) 
Gender, n (%) Male,  
Female 
4,689 (56%) 
3,690 (44%) 
2 165 (53%) 
1,923 (47%) 
2,524 (59%) 
1,767 (41%) 
Previous psychiatric diagnosis, n (%) 2,004 (24%) 808 (20%) 1196 (28%) 
Targeted AEDs, n (%) 
 
 
 
 
 
 
Other AEDs, n (%) 
 
Carbamazepine 
Lamotrigine 
Levetiracetam 
Oxcarbazepine 
Topiramate 
Valproic acid 
 
 
1,907 (23%) 
1,888 (23%) 
2,182 (26%) 
239 (3%) 
588 (7%) 
3,892 (46%) 
 
4,163 (50%) 
1,104 (27%) 
766 (19%) 
1,646 (40%) 
121 (3%) 
396 (10%) 
1,176 (29%) 
 
2,083 (51%) 
803 (19%) 
1,122 (26%) 
536 (12%) 
118 (3%) 
192 (4%) 
2,716 (63%) 
 
2,080 (48%) 
Only one targeted AED, n (%) 6,338 (76%) 3,103 (76%) 3,235 (75%) 
Strict monotherapy, n (%) 3,462 (41%) 1,649 (40%) 1,813 (42%) 
AED-free patients were defined as patients who had only targeted AED brand name dispensations 
before the control period; which means no prior exposure to AED generics before the control period. 
Conversely, patients who had at least one dispensation of the generic drug before control period were 
defined as AED non-free patients. 
Presence of previous psychiatric diagnosis is based on inscription in long-term disease (LTD) with an 
ICD-10 code corresponding to a psychiatric disorder 
Targeted anti-epileptic drugs (AEDs), i.e. AEDs with at least one available generic form on the French 
market, were: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproic 
acid. 
Strict monotherapy was defined as dispensations of only one targeted AED without any concurrent 
use of other AEDs during the year preceding the index event date. These other (not targeted) AEDs 
were the following: barbiturates, benzodiazepines (clonazepam, clobazam, diazepam), hydantoins, 
GABA analogs (gabapentin, pregabalin). They were identified by their CIP number. They belong to the 
following ATC classes: N03AA, N03AB, N03AD, N03AE, N05BA09, N05BA01, N03AF03, N03AF04, 
N03AG04, N03AG05, N03AG06, N03AX12, N03AX15, N03AX16, N03AX17 and N03AX18. 
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Table 2 Number of patients according to the occurrence of brand to generic 
substitution in case and control periods 
 
Generic 
substitution 
Case period 
No Yes 
Control 
period 
No 7222 478 
Yes 491 188 
19 
 
Table 3 Number of patients experiencing a brand-generic substitution according to 
antiepileptic drug, user profile (generic-free or not) and period as well as number of 
occurrence of non-seizure related hospitalization according user profile (generic-free 
or not) and period. 
 
 
Free patients 
N = 4 088 
Non free patients 
N = 4 291 
 
Control 
period 
Case period 
Control 
period 
Case period 
AED substitution     
Carbamazepine 15 21 98 87 
Lamotrigine 31 32 153 155 
Oxcarbazepine 2 1 9 7 
Topiramate 8 12 17 11 
Valproic acid 54 60 317 304 
Any of them 107 124 572 542 
Non-seizure 
related 
hospitalization 
496 601 584 687 
AED-free patients were defined as patients who had only targeted AED brand name dispensations 
before the control period; which means no prior exposure to AED generics before the control period. 
Conversely, patients who had at least one dispensation of the generic drug before control period were 
defined as AED non-free patients. 
20 
 
Table 4 Crude and non-seizure-related-hospitalization-adjusted odds ratios (OR) 
relative to brand-to-generic substitution (any targeted antiepileptic drug (AED) or 
narrow therapeutic index AEDs) for different subgroups of patients 
 
Any targeted AEDs 
Narrow therapeutic 
index 
Unadjusted analysis Adjusted analysis 
Population 
Conditional OR 
(95% CI) 
p-value 
Conditional OR 
(95% CI) 
p-value 
All patients 
0.97 (0.86–1.10) 
0.95 (0.82–1.11) 
 
0.97 (0.85–1.10) 
0.95 (0.81–1.10) 
 
Men 
1.02 (0.86–1.20) 
1.01 (0.83–1.22) 0.42 
0.37 
1.01 (0.86–1.20) 
1.00 (0.82–1.21) 0.44 
0.39 
Women 
0.92 (0.76–1.11) 
0.88 (0.69–1.11) 
0.91 (0.76–1.11) 
0.87 (0.68–1.11) 
Free patients 
1.20 (0.90–1.61) 
1.21 (0.84–1.75) 0.111 
0.160 
1.20 (0.90–1.61) 
1.20 (0.83–1.73) 0.107 
0.171 
Non free patients 
0.93 (0.81–1.07) 
0.91 (0.77–1.07) 
0.92 (0.80–1.06) 
0.90 (0.77–1.06) 
Patients following a 
strict monotherapy 
0.95 (0.77–1.16) 
0.90 (0.70–1.15) 0.73 
0.55 
0.93 (0.76–1.15) 
0.88 (0.69–1.13) 0.67 
0.48 Patients not following 
a strict monotherapy 
0.99 (0.84–1.16) 
0.99 (0.82–1.19) 
0.99 (0.84–1.16) 
0.99 (0.82–1.19) 
Patients < 40 years 
old at index date 
1.07 (0.84–1.35) 
0.99 (0.74–1.31) 
0.54 
0.49 
1.06 (0.84–1.35) 
0.98 (0.74–1.31) 
0.52 
0.45 
Patients  40-69 years 
old at index date 
0.97 (0.81–1.16) 
0.99 (0.81–1.22) 
0.97 (0.81–1.15) 
0.99 (0.81–1.21) 
Patients ≥ 70 years 
old at index date 
0.87 (0.66–1.15) 
0.78 (0.55–1.12) 
0.86 (0.65–1.14) 
0.77 (0.54–1.10) 
P values are for homogeneity testing; 
AED-free patients were defined as patients who had only targeted AED brand name dispensations 
before the control period; which means no prior exposure to AED generics before the control period. 
Conversely, patients who had at least one dispensation of the generic drug before control period were 
defined as AED non-free patients. 
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Table 5 Sensitivity analyses 
 
3-days induction 
1-day induction 
5-days-induction 
3-months case and 
control period 
28-day case and control 
period 
Population 
Conditional OR 
(95% CI) 
p-value 
Conditional OR 
(95% CI) 
p-value 
All patients 
0.97 (0.86–1.10) 
0.99 (0.87–1.12) 
0.98 (0.86–1.11) 
 
1.07 (0.88–1.30) 
1.12 (0.92–1.35) 
1.01 (0.84–1.23) 
 
Men 
1.02 (0.86–1.20) 
1.01 (0.86–1.20) 
1.04 (0.88–1.23) 0.42 
0.63 
0.28 
1.03 (0.79–1.33) 
1.07 (0.83–1.39) 
0.96 (0.74–1.24) 0.63 
0.65 
0.51 
Women 
0.92 (0.76–1.11) 
0.95 (0.79–1.15) 
0.90 (0.74–1.09) 
1.13 (0.84–1.51) 
1.17 (0.88–1.56) 
1.09 (0.81–1.47) 
Free patients 
1.20 (0.90–1.61) 
1.28 (0.96–1.70) 
1.22 (0.91–1.64) 0.11 
0.05 
0.09 
1.12 (0.74–1.71) 
1.21 (0.81–1.83) 
1.10 (0.72–1.68) 0.80 
0.64 
0.68 
Non free patients 
0.93 (0.81–1.07) 
0.93 (0.81–1.07) 
0.93 (0.81–1.07) 
1.06 (0.85–1.31) 
1.09 (0.88–1.35) 
0.99 (0.80–1.23) 
Patients following a 
strict monotherapy 
0.95 (0.77–1.16) 
0.96 (0.78–1.18) 
0.97 (0.79–1.19) 0.73 
0.70 
0.92 
0.97 (0.71–1.34) 
1.01 (0.73–1.40) 
0.84 (0.62–1.16) 0.47 
0.47 
0.15 Patients not following 
a strict monotherapy 
0.99 (0.84–1.16) 
1.01 (0.86–1.18) 
0.98 (0.84–1.15) 
1.13 (0.89–1.44) 
1.18 (0.93–1.49) 
1.13 (0.89–1.44) 
Patients < 40 years 
old at index date 
1.07 (0.84–1.35) 
1.07 (0.85–1.36) 
1.04 (0.82–1.32) 
0.54 
0.45 
0.74 
1.11 (0.77–1.60) 
1.41 (0.98–2.03) 
1.05 (0.73–1.52) 
0.57 
0.16 
0.71 
Patients  40-69 years 
old at index date 
0.97 (0.81–1.16) 
1.00 (0.84–1.19) 
0.97 (0.81–1.16) 
0.98 (0.75–1.28) 
0.94 (0.72–1.22) 
0.95 (0.73–1.23) 
Patients ≥ 70 years 
old at index date 
0.87 (0.66–1.15) 
0.85 (0.65–1.13) 
0.90 (0.68–1.19) 
1.29 (0.83–2.03) 
1.29 (0.83–2.00) 
1.17 (0.75–1.84) 
P values are for homogeneity testing; AED-free patients were defined as patients who had only 
targeted AED brand name dispensations before the control period; which means no prior exposure to 
AED generics before the control period. Conversely, patients who had at least one dispensation of the 
generic drug before control period were defined as AED non-free patients.
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Figure 1 Flow chart 
 
 
